Completed PHASE2 INTERVENTIONAL 1-arm NCT01321879

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Phase II, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Sponsor: M.D. Anderson Cancer Center

Conditions Bacteremia Infection

Interventions Telavancin

Updated 8 times since 2017 Last updated: Dec 12, 2019 Started: Mar 31, 2011 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Bacteremia and Infection, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 8 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2
Oct 2018 — Jan 2020 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Theravance Biopharma

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States